<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: development efforts on products", fill: "#f4c430"},
{source: "3: development efforts on products", target: "3: complement", fill: "#f4c430"},
{source: "3: complement", target: "3: existing product lines", fill: "#f4c430"},
{source: "3: existing product lines", target: "3: no competitors", fill: "#f4c430"},
{source: "3: development efforts on products", target: "4: fulltime employees", fill: "#f0e130"},
{source: "4: fulltime employees", target: "4: product research", fill: "#f0e130"},
{source: "4: product research", target: "4: development", fill: "#f0e130"},
{source: "4: fulltime employees", target: "6: December ", fill: "#ff9f00"},
{source: "6: December ", target: "20: manufacturing", fill: "#e4d96f"},
{source: "20: manufacturing", target: "20: pharmaceutical products", fill: "#e4d96f"},
{source: "20: pharmaceutical products", target: "20: highly competitive with", fill: "#e4d96f"},
{source: "20: highly competitive with", target: "20: established manufacturers suppliers", fill: "#e4d96f"},
{source: "20: established manufacturers suppliers", target: "20: distributors actively", fill: "#e4d96f"},
{source: "20: manufacturing", target: "37: sufficient quantities", fill: "#039"},
{source: "37: sufficient quantities", target: "37: components", fill: "#039"},
{source: "37: components", target: "37: manufacture", fill: "#039"},
{source: "37: manufacture", target: "37: products as", fill: "#039"},
{source: "37: products as", target: "37: which could", fill: "#039"},
{source: "37: which could", target: "37: financial condition", fill: "#039"},
{source: "37: financial condition", target: "37: operations", fill: "#039"},
{source: "37: sufficient quantities", target: "39: Those ", fill: "#e68fac"},
{source: "39: Those ", target: "39: distributors", fill: "#e68fac"},
{source: "39: Those ", target: "START_HERE", fill: "#e68fac"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Human_development">Human development</a></td>
      <td>The Human Development Index (HDI) is a statistic composite index of life expectancy, education (mean years of schooling completed and expected years of schooling upon entering the education system), and per capita income indicators, which are used to rank countries into four tiers of human development. A country scores a higher level of HDI when the lifespan is higher, the education level is higher, and the gross national income GNI (PPP) per capita is higher.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_hell">Development hell</a></td>
      <td>Development hell, development purgatory, and development limbo are media and software industry jargon for a project, concept, or idea that remains in development for an especially long time, often moving between different crews, scripts, game engines, or studios before it progresses to production, if it ever does. Projects in development hell are usually not released until development has reached a satisfying state worthy of being released, ready for production.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Professional_development">Professional development</a></td>
      <td>Professional development is learning to earn or maintain professional credentials such as academic degrees to formal coursework, attending conferences, and informal learning opportunities situated in practice. It has been described as intensive and collaborative, ideally incorporating an evaluative stage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_17">December 17</a></td>
      <td>December 17 is the 351st day of the year (352nd in leap years) in the Gregorian calendar;  14 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n497 BC – The first Saturnalia festival was celebrated in ancient Rome.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_10">December 10</a></td>
      <td>December 10 is the 344th day of the year (345th in leap years) in the Gregorian calendar;  21 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n1317 – The "Nyköping Banquet": King Birger of Sweden treacherously seizes his two brothers Valdemar, Duke of Finland and Eric, Duke of Södermanland, who were subsequently starved to death in the dungeon of Nyköping Castle.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1924_German_federal_election">December 1924 German federal election</a></td>
      <td>Federal elections were held in Germany on 7 December 1924, the second that year after the Reichstag had been dissolved on 20 October. The Social Democratic Party remained the largest party in the Reichstag, receiving an increased share of the vote and winning 131 of the 493 seats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1">December 1</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2016_in_aviation">2016 in aviation</a></td>
      <td>This is a list of aviation-related events from 2016.\n\n\n== Events ==\n\n\n=== January ===\nThe Government of Italy permitted United States unmanned aerial vehicles (UAVs or drones) to fly strike missions from Naval Air Station Sigonella in Sicily where the US has operated unarmed surveillance UAVs since 2001 against Islamic State targets in Libya, but only if they are "defensive," protecting U.S. forces or rescuers retrieving downed pilots.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_18">December 18</a></td>
      <td>December 11 is the 345th day of the year (346th in leap years) in the Gregorian calendar;  20 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n220 – Emperor Xian of Han is forced to abdicate the throne by Cao Cao's son Cao Pi, ending the Han dynasty.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_26">December 26</a></td>
      <td>December 15 is the 349th day of the year (350th in leap years) in the Gregorian calendar;  16 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n533 – Vandalic War: Byzantine general Belisarius defeats the Vandals, commanded by King Gelimer, at the Battle of Tricamarum.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_8">December 8</a></td>
      <td>December 3 is the 337th day of the year (338th in leap years) in the Gregorian calendar;  28 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n915 – Pope John X crowns Berengar I of Italy as Holy Roman Emperor (probable date).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/General_Film_Distributors">General Film Distributors</a></td>
      <td>General Film Distributors (GFD), later known as J. Arthur Rank Film Distributors and Rank Film Distributors Ltd., was a British film distribution company based in London. It was active between 1935 and 1996, and from 1937 it was part of the Rank Organisation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_film_distributors_by_country">List of film distributors by country</a></td>
      <td>This is a list of motion picture distributors, past and present, sorted alphabetically by country.\n\n\n== Albania ==\nConstantin Film\nUnited International Pictures\n\n\n== Argentina ==\nBuena Vista International\nWarner Bros.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_director">Operations director</a></td>
      <td>The role of operations director generally encompasses the oversight of operational aspects of company strategy with responsibilities to ensure operation information is supplied to the chief executive and the board of directors as well as external parties.\n\n\n== Description ==\nThe role of operations director can vary according to the size of a company, and at some companies many even encompass some or all the functions of a chief operating officer.The Institute of Directors of the United Kingdom defines the role as overseeing "all operational aspects of company strategy" and "responsible for the flow of operations information to the chief executive, the board and, where necessary, external parties such as investors or financial institutions".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hartford_Distributors_shooting">Hartford Distributors shooting</a></td>
      <td>The Hartford Distributors shooting was a mass shooting that occurred on August 3, 2010, in Manchester, Connecticut, United States. The location of the crime was a warehouse owned by Hartford Distributors, a beer distribution company.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Brewers'_Distributor">Brewers' Distributor</a></td>
      <td>Brewers' Distributor Ltd. (BDL) is a Canadian company that distributes beer throughout the four western provinces and three northern territories.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Quality_Distributors">Quality Distributors</a></td>
      <td>Quality Distributors FC are a professional association football (soccer) club in Guam. They play in the Guam Soccer League.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Titan_Distributors">Titan Distributors</a></td>
      <td>Titan Distributors was a British comic book distributor which existed from 1978 to 1993, when it was acquired by a larger U.S. distributor. Operated by Nick Landau, Mike Lake, and Mike Luckman, Titan Distributors supplied comics, science fiction, and other genre products to retailers all over the United Kingdom.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Diamond_Comic_Distributors">Diamond Comic Distributors</a></td>
      <td>Diamond Comic Distributors, Inc. (often called Diamond Comics, DCD, or casually Diamond) is an American comic book distributor serving retailers in North America and worldwide.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sony_Pictures_Motion_Picture_Group">Sony Pictures Motion Picture Group</a></td>
      <td>Sony Pictures Entertainment Motion Picture Group (commonly known as Sony Pictures Motion Picture Group, formerly known as the Columbia TriStar Motion Picture Group until 2013, and abbreviated as SPMPG) is a division of Sony Pictures Entertainment to manage its motion picture operations. It was launched in 1998 by integrating the businesses of Columbia Pictures Industries, Inc.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>AKORN INC      Regulation” <font color="blue">on page seven</font> and Item 1A <font color="blue">Risk Factors</font> — Our <font color="blue">growth depends on</font>     our  ability  to timely develop <font color="blue"><font color="blue">additional</font> <font color="blue"><font color="blue">pharmaceutical</font> products</font></font> and     <font color="blue"><font color="blue">manufacturing</font> <font color="blue">capabilities</font></font></td>
    </tr>
    <tr>
      <td>We  also  maintain a business <font color="blue"><font color="blue">development</font> program</font> that identifies     <font color="blue">potential product acquisition</font> or <font color="blue">product licensing candidates</font></td>
    </tr>
    <tr>
      <td>We have     focused our business <font color="blue"><font color="blue">development</font> efforts on products</font> that <font color="blue">complement</font> our     <font color="blue">existing product lines</font> and that have few or <font color="blue">no <font color="blue">competitors</font></font> in the market</td>
    </tr>
    <tr>
      <td>5       _________________________________________________________________    [55]Table of <font color="blue">Contents       </font>     At <font color="blue">December </font>31, 2005, ten of our full-time employees were involved in     <font color="blue">product research</font> and business <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Research and <font color="blue">development</font> costs are expensed as incurred</td>
    </tr>
    <tr>
      <td>Such costs     amounted to dlra4cmam510cmam000, dlra1cmam861cmam000, and dlra1cmam465cmam000, for the years ended     <font color="blue">December </font>31, 2005, 2004, and 2003, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>Patents, Trademarks and Proprietary Rights</td>
    </tr>
    <tr>
      <td>We consider the protection     of <font color="blue">discoveries</font> in <font color="blue"><font color="blue">connection</font> with</font> our <font color="blue">development</font> activities important to     our  business</td>
    </tr>
    <tr>
      <td>We have sought, and intend to continue to seek, patent     protection in the <font color="blue">United States </font>and selected <font color="blue">foreign countries</font> where deemed     <font color="blue">appropriate</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had received seven US patents and     had <font color="blue">four <font color="blue">additional</font></font> US <font color="blue">patent <font color="blue">applications</font> pending</font></td>
    </tr>
    <tr>
      <td>We also rely upon trademarks, trade secrets, unpatented proprietary     know-how and <font color="blue">continuing technological innovation</font> to maintain and develop our     <font color="blue"><font color="blue">competitive</font> position</font></td>
    </tr>
    <tr>
      <td>We enter into confidentiality <font color="blue">agreements</font> with certain     of our employees pursuant to <font color="blue">which such employees agree</font> to assign to us any     <font color="blue">inventions</font>  relating to our business made <font color="blue">by them while</font> in our employ</td>
    </tr>
    <tr>
      <td>However,  there  can  be  no  assurance that <font color="blue">others may</font> not acquire or     <font color="blue">independently</font> develop similar <font color="blue">technology</font> or, if patents are not <font color="blue">issued with</font>     respect to products arising <font color="blue">from research</font>, that we will be able to maintain     information pertinent to such research as proprietary <font color="blue">technology</font> or trade     secrets</td>
    </tr>
    <tr>
      <td>See Item 1A <font color="blue">Risk Factors</font> — Our patents and <font color="blue">proprietary rights may</font>     not <font color="blue">adequately protect</font> our products and processes</td>
    </tr>
    <tr>
      <td>At  <font color="blue">December </font>31, 2005, we had 327 full-time     employees,  269 of whom were <font color="blue">employed by us</font> and 58 by our wholly owned     subsidiary, Akorn (New Jersey), Inc</td>
    </tr>
    <tr>
      <td>Akorn-Strides, LLC has <font color="blue">no employees</font></td>
    </tr>
    <tr>
      <td>We     believe  we  enjoy good <font color="blue">relations with</font> our employees, none of whom are     <font color="blue">represented by</font> a <font color="blue">collective bargaining agent</font></td>
    </tr>
    <tr>
      <td>The marketing and <font color="blue">manufacturing</font> of <font color="blue"><font color="blue">pharmaceutical</font> products</font>     is highly <font color="blue">competitive</font>, with many established <font color="blue">manufacture</font>rs, suppliers and     <font color="blue"><font color="blue"><font color="blue">distributor</font>s</font> actively</font> engaged in all phases of the business</td>
    </tr>
    <tr>
      <td>Most of our     <font color="blue">competitors</font>  have <font color="blue">substantially</font> greater financial and other resources,     including  greater  sales  volume,  larger  sales  forces  and greater     <font color="blue">manufacturing</font> capacity</td>
    </tr>
    <tr>
      <td>See Item 1A <font color="blue">Risk Factors</font> — Our industry is very     <font color="blue">competitive</font>; changes in <font color="blue">technology</font> could render our <font color="blue">products obsolete</font></td>
    </tr>
    <tr>
      <td>The companies that <font color="blue">compete with</font> our ophthalmic segment include Alcon     Laboratories, Inc, Allergan Pharmaceuticals, Inc, Novartis and Bausch &amp;     Lomb, Inc</td>
    </tr>
    <tr>
      <td>The ophthalmic segment <font color="blue">competes <font color="blue">primarily on</font></font> the basis of price     and service</td>
    </tr>
    <tr>
      <td>The companies that <font color="blue">compete with</font> our injectable segment include both     generic  and  name  brand  companies  such  as Hospira, Teva, American     <font color="blue">Pharmaceutical </font> Partners  and  Baxter</td>
    </tr>
    <tr>
      <td>The injectable segment competes     <font color="blue">primarily on</font> the basis of price</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>in our <font color="blue">contract services</font> segment include Baxter, Hospira     and Patheon</td>
    </tr>
    <tr>
      <td>The <font color="blue">contract services</font> segment <font color="blue">competes <font color="blue">primarily on</font></font> the basis     of price and <font color="blue">technical <font color="blue">capabilities</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Suppliers and Customers</font></td>
    </tr>
    <tr>
      <td>No     supplier of <font color="blue">products accounted</font> for more than 10prca of our purchases in 2003</td>
    </tr>
    <tr>
      <td>We require a supply of <font color="blue">quality raw materials</font> and <font color="blue">components</font> to <font color="blue">manufacture</font>     and package <font color="blue"><font color="blue">pharmaceutical</font> products</font> for ourselves and for <font color="blue">third parties with</font>     which we have contracted</td>
    </tr>
    <tr>
      <td>The principal <font color="blue">components</font> of our products are     active  and  <font color="blue">inactive <font color="blue">pharmaceutical</font> ingredients</font> and <font color="blue">certain packaging</font>     materials</td>
    </tr>
    <tr>
      <td>Many of these <font color="blue">components</font> are available from only a single source     and, in the case of many of our ANDAs and NDAs, <font color="blue">only one supplier</font> of raw     materials  has been identified</td>
    </tr>
    <tr>
      <td><font color="blue">Because FDA </font>approval of drugs requires     <font color="blue">manufacture</font>rs to specify their <font color="blue">proposed suppliers</font> of <font color="blue">active ingredients</font> and     <font color="blue">certain packaging</font> materials in their <font color="blue">applications</font>, FDA approval of any new     <font color="blue">supplier would</font> be required if <font color="blue">active ingredients</font> or <font color="blue">such packaging materials</font>     were <font color="blue">no longer available from</font> the <font color="blue">specified supplier</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">qualification</font> of a     <font color="blue">new supplier could delay</font> our <font color="blue">development</font> and <font color="blue">marketing efforts</font></td>
    </tr>
    <tr>
      <td>If for any     reason we are unable to obtain <font color="blue">sufficient quantities</font> of any of the raw     materials or <font color="blue">components</font> required to produce and package our products, we may     not be able to <font color="blue">manufacture</font> our <font color="blue">products as</font> planned, <font color="blue">which could</font> have a     material adverse effect on our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>A small number of large <font color="blue">wholesale drug <font color="blue"><font color="blue">distributor</font>s</font> account</font> for a large     portion  of  our  gross sales, revenues and <font color="blue">accounts receivable</font></td>
    </tr>
    <tr>
      <td><font color="blue">Those     </font><font color="blue"><font color="blue">distributor</font>s</font> are:       •   AmerisourceBergen Corporation (“AmerisourceBergen”)         •   <font color="blue">Cardinal </font>Health, Inc</td>
    </tr>
    <tr>
      <td>(“Cardinal”); and         •   McKesson Drug Company (“McKesson”)</td>
    </tr>
    <tr>
      <td>6       _________________________________________________________________    [56]Table of <font color="blue">Contents       </font>     These three <font color="blue">wholesale drug <font color="blue"><font color="blue">distributor</font>s</font> account</font>ed for approximately 69prca     of our total gross sales and 46prca of our revenues in 2005, and 76prca of our     gross <font color="blue">accounts receivable</font> as of <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>The <font color="blue">difference between</font>     gross sales and revenue is that gross sales do not reflect the <font color="blue">deductions</font>     for chargebacks, rebates and <font color="blue">product returns</font> (See Item 7</td>
    </tr>
    <tr>
      <td>The <font color="blue">percentages</font> of gross sales, revenue and     gross <font color="blue">trade receivables attributed</font> to each of these <font color="blue">three wholesale drug</font>     <font color="blue"><font color="blue">distributor</font>s</font> for the years ended <font color="blue">December </font>31, 2005 and <font color="blue">December </font>31, 2004     were as follows:             2005   2004         Gross           Gross Accounts   Gross           Gross Accounts         Sales   Revenue   Receivable   Sales   Revenue   Receivable     <font color="blue">AmerisourceBergen  </font>       24 %     16 %     28 %     14 %     10 %     17 %     <font color="blue">Cardinal </font>        28 %     19 %     29 %     25 %     20 %     51 %     <font color="blue">McKesson         </font>17 %     11 %     19 %     18 %     16 %     6 %            AmerisourceBergen,  <font color="blue">Cardinal </font>and McKesson are <font color="blue"><font color="blue">distributor</font>s</font> of our     <font color="blue">products as</font> well as a <font color="blue">broad range</font> of <font color="blue">health care products</font> for many other     companies</td>
    </tr>
    <tr>
      <td>None of these <font color="blue"><font color="blue">distributor</font>s</font> is an end user of our products</td>
    </tr>
    <tr>
      <td>If     sales to any one of these <font color="blue"><font color="blue">distributor</font>s</font> were to diminish or cease, we believe     that the end users of our <font color="blue">products would find</font> little <font color="blue">difficulty</font> obtaining     our <font color="blue">products either directly from us</font> or from another <font color="blue">distributor</font></td>
    </tr>
    <tr>
      <td>However,     the loss of one or more of these <font color="blue"><font color="blue">distributor</font>s</font>, together with a delay or     <font color="blue">inability</font> to secure an <font color="blue">alternative</font> <font color="blue">distribution</font> source for end users, could     have  a  material  <font color="blue">negative impact on</font> our revenue, business, financial     condition and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We consider our business <font color="blue">relationships</font>     with  these  <font color="blue">three wholesalers</font> to be in good standing and have fee for     <font color="blue">services contracts with</font> <font color="blue">Cardinal </font>and McKesson</td>
    </tr>
    <tr>
      <td>We have <font color="blue">also established</font> a     fee  for  service  contract  with  AmerisourceBergen,  which  began in     January 2006</td>
    </tr>
    <tr>
      <td>A change in purchasing patterns, a decrease in inventory     levels,  an  increase in returns of our products, delays in purchasing     products and delays in payment for <font color="blue">products by one</font> or more <font color="blue"><font color="blue">distributor</font>s</font> also     could have a material <font color="blue">negative impact on</font> our revenue, business, financial     condition and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>See Item 1A Risk factors — We <font color="blue">depend on</font>     a  small number of <font color="blue"><font color="blue">distributor</font>s</font>, the loss of any of <font color="blue">which could</font> have a     material adverse effect          <font color="blue">Backorders</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had approximately dlra1cmam400cmam000 of     <font color="blue">products on backorder as compared</font> to approximately dlra2cmam400cmam000 of <font color="blue">backorders</font>     as  of <font color="blue">December </font>31, 2004</td>
    </tr>
    <tr>
      <td>This decrease in <font color="blue">backorders</font> is due to higher     <font color="blue">production levels</font> in 2005</td>
    </tr>
    <tr>
      <td>We anticipate filling all current open <font color="blue">backorders</font>     during 2006</td>
    </tr>
    <tr>
      <td><font color="blue">Government Regulation</font></td>
    </tr>
    <tr>
      <td><font color="blue">Pharmaceutical </font><font color="blue">manufacture</font>rs and <font color="blue"><font color="blue">distributor</font>s</font>     are subject to extensive <font color="blue">regulation by <font color="blue">government</font> agencies</font>, including the     FDA,  the  Drug  Enforcement Administration (“DEA”), the Federal Trade     Commission (“FTC”) and other federal, state and <font color="blue">local agencies</font></td>
    </tr>
    <tr>
      <td>The federal     Food, Drug and Cosmetic Act (the “FDC Act”), the Controlled Substance Act     and  other  federal  statutes  and <font color="blue">regulations</font> govern or influence the     <font color="blue">development</font>,  testing, <font color="blue">manufacture</font>, labeling, storage and promotion of     products that we <font color="blue">manufacture</font> and market</td>
    </tr>
    <tr>
      <td>The FDA inspects drug <font color="blue">manufacture</font>rs     and  storage  <font color="blue">facilities</font> to determine <font color="blue">compliance with</font> its current Good     Manufacturing Practices (“cGMP”) <font color="blue">regulations</font>, non-<font color="blue">compliance with</font> which can     result in fines, recall and seizure of products, total or <font color="blue">partial suspension</font>     of production, refusal to approve NDAs and criminal <font color="blue">prosecution</font></td>
    </tr>
    <tr>
      <td><font color="blue">The FDA     </font>also has the authority to <font color="blue">revoke approval</font> of <font color="blue">drug products</font></td>
    </tr>
    <tr>
      <td>FDA  approval is required before any drug can be <font color="blue">manufacture</font>d and     marketed</td>
    </tr>
    <tr>
      <td>New drugs require the filing of an NDA, including <font color="blue">clinical studies</font>     <font color="blue">demonstrating</font> the safety and efficacy of the drug</td>
    </tr>
    <tr>
      <td>Generic drugs, which are     <font color="blue">equivalents</font> of existing, off-patent brand <font color="blue">name drugs</font>, require the filing of     an <font color="blue">ANDA An ANDA </font>does not, for the most part, require <font color="blue">clinical studies</font> since     safety  and  efficacy  have  already  <font color="blue">been demonstrated by</font> the product     <font color="blue">originator</font></td>
    </tr>
    <tr>
      <td>However,  the  ANDA  must  provide data <font color="blue">demonstrating</font> the     <font color="blue">equivalency</font> of the <font color="blue">generic formulation</font> in terms of <font color="blue">bioavailability</font></td>
    </tr>
    <tr>
      <td>The time     required by the FDA to review and approve <font color="blue">NDAs and ANDAs </font>is variable and     beyond our control</td>
    </tr>
    <tr>
      <td>The  FDA  issued a <font color="blue"><font color="blue">Warning Letter</font> </font>to us in     October 2000 following a <font color="blue">routine inspection</font> of our Decatur <font color="blue">manufacturing</font>     <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>An FDA <font color="blue"><font color="blue">Warning Letter</font> </font>is intended to provide notice to a company     of violations of the <font color="blue">laws administered by</font> the FDA and to <font color="blue">elicit voluntary</font>     corrective  action</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">Warning Letter</font> </font><font color="blue">cited violations</font> of <font color="blue">regulatory</font>     <font color="blue">requirements</font> identified during the 2000 inspection and requested that we     take <font color="blue">corrective actions</font></td>
    </tr>
    <tr>
      <td>Under the terms of the <font color="blue">Warning Letter</font>, we were     unable  to  obtain any approvals to <font color="blue">market <font color="blue">new products</font></font> and <font color="blue">government</font>     agencies  were  notified  of  our non-compliant status</td>
    </tr>
    <tr>
      <td><font color="blue">Additional FDA     </font>inspections in 2002, 2003 and 2004 identified <font color="blue">additional</font> and recurring     violations resulting in continuance of the <font color="blue">Warning Letter</font></td>
    </tr>
    <tr>
      <td>During this time,     the FDA <font color="blue">initiated no enforcement action</font></td>
    </tr>
    <tr>
      <td>Since 2000, and in response to the <font color="blue">violations cited by</font> the FDA, we     implemented a <font color="blue">comprehensive systematic corrective action</font> plan at our <font color="blue">Decatur     </font><font color="blue">manufacturing</font> <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>We maintained <font color="blue">regular communications with</font> the FDA     and provided periodic progress reports</td>
    </tr>
    <tr>
      <td>7       _________________________________________________________________    [57]Table of <font color="blue">Contents       </font>     On <font color="blue">December </font>13, 2005, the FDA <font color="blue">notified us</font> that we had <font color="blue">satisfactorily</font>     implemented <font color="blue">corrective actions</font> and the FDA had determined that our <font color="blue">Decatur     </font><font color="blue">manufacturing</font> <font color="blue">facility</font> was in substantial <font color="blue">compliance with</font> cGMP <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Consequently, the <font color="blue">restrictions</font> of the <font color="blue"><font color="blue">Warning Letter</font> </font>were removed and we     <font color="blue">became eligible</font> for <font color="blue">new product approvals</font> for products <font color="blue">manufacture</font>d at our     Decatur <font color="blue">manufacturing</font> <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>While under the <font color="blue"><font color="blue">Warning Letter</font> </font><font color="blue">restrictions</font> from 2000 to 2005, our     <font color="blue">inability</font> to <font color="blue">fully utilize</font> the <font color="blue">capabilities</font> of the Decatur <font color="blue">manufacturing</font>     <font color="blue">facility</font> had a material adverse effect on our business, <font color="blue">financial condition</font>     and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Product Recalls</font></td>
    </tr>
    <tr>
      <td>In     <font color="blue">February </font>2003, we <font color="blue">recalled two products</font>, Fluress and Fluoracaine, due to     container/closure integrity problems resulting in <font color="blue">leaking containers</font></td>
    </tr>
    <tr>
      <td>The     recall was <font color="blue">classified by</font> the FDA as a <font color="blue">Class II Recall</font>, which means that the     use of, or exposure to, a <font color="blue">violative product may</font> cause temporary or <font color="blue">medically</font>     <font color="blue">reversible adverse health consequences</font> or that the <font color="blue">probability</font> of serious     <font color="blue">health consequences as</font> a result of such use or exposure is remote</td>
    </tr>
    <tr>
      <td>The     <font color="blue">financial impact</font> of this recall was not material to us as our customers did     not hold <font color="blue">significant inventories</font> of these products</td>
    </tr>
    <tr>
      <td>In  March 2003, as a result <font color="blue">of the FDA </font>inspections performed from     <font color="blue">December </font>10, 2002 to <font color="blue">February </font>6, 2003, we recalled twenty-four lots of     product produced from the period <font color="blue">December </font>2001 to June 2002 in one of our     <font color="blue">production rooms at</font> our Decatur <font color="blue">manufacturing</font> <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>The majority of the     lots recalled were for <font color="blue">third party contract customer products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Subsequent </font>to     this decision and after <font color="blue">discussions</font> with the FDA, eight of the original     twenty-four lots were <font color="blue">exempted from</font> the <font color="blue">recall due</font> to <font color="blue">medical necessity</font></td>
    </tr>
    <tr>
      <td>The     recall was <font color="blue">classified by</font> the FDA as a <font color="blue">Class II Recall</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">financial impact</font>     of  this  recall  was not material to us as our customers did not hold     <font color="blue">significant inventories</font> of these products</td>
    </tr>
    <tr>
      <td>We  also  <font color="blue">manufacture</font>  and  distribute  several     controlled-drug substances, the <font color="blue">distribution</font> and handling of which are     <font color="blue">regulated by</font> the DEA Failure to comply with DEA <font color="blue">regulations</font> can result in     fines or seizure of product</td>
    </tr>
    <tr>
      <td>On  March 6,  2002,  we  received a <font color="blue">letter from</font> the <font color="blue">United States </font>    Attorney’s Office, Central District of Illinois, Springfield, Illinois,     <font color="blue">advising us</font> that the DEA had referred a matter to that office for a possible     <font color="blue">civil legal action</font> for alleged violations of the Comprehensive Drug Abuse     Prevention Control Act of 1970, 21 USC § 801 et</td>
    </tr>
    <tr>
      <td>(“Comprehensive     Drug Act”), and <font color="blue">regulations</font> promulgated thereunder</td>
    </tr>
    <tr>
      <td>The alleged violations     relate  to  record  keeping  and  <font color="blue">controls surrounding</font> the storage and     <font color="blue">distribution</font> of <font color="blue">controlled substances</font></td>
    </tr>
    <tr>
      <td>Without admitting to any of the     <font color="blue">allegations</font>, on November 6, 2002, we <font color="blue">entered into</font> a <font color="blue"><font color="blue">Civil Consent Decree </font>    </font>with the DEA (the “Civil Consent Decree”)</td>
    </tr>
    <tr>
      <td>Under terms of the Civil Consent     Decree, <font color="blue">without admitting</font> any of the <font color="blue">allegations</font> in the <font color="blue">complaint from</font> the     DEA, we agreed to pay a fine of dlra100cmam000, upgrade our <font color="blue">security system</font> and to     remain in substantial <font color="blue">compliance with</font> the <font color="blue">Comprehensive Drug Act</font></td>
    </tr>
    <tr>
      <td>If we     failed  to remain in substantial <font color="blue">compliance during</font> the two-year period     following the entry of <font color="blue">the Civil Consent Decree</font>, we, in addition to other     possible sanctions, might have been held in contempt of court and ordered to     pay an <font color="blue">additional</font> dlra300cmam000 fine</td>
    </tr>
    <tr>
      <td>We completed the upgrades to our security     system  in  2003  and  have received no further notice from the DEA in     <font color="blue"><font color="blue">connection</font> with</font> <font color="blue">the Civil Consent Decree</font></td>
    </tr>
    <tr>
      <td>The two-year compliance period     <font color="blue">lapsed on</font> November 6, 2004</td>
    </tr>
    <tr>
      <td>We were inspected by the DEA in <font color="blue">February </font>2005     and the DEA has not <font color="blue">informed us</font> of any <font color="blue">further violations</font></td>
    </tr>
    <tr>
      <td>We do not anticipate any material adverse effect from     <font color="blue">compliance with</font> federal, state and <font color="blue">local provisions</font> that have <font color="blue">been enacted</font>     or <font color="blue">adopted regulating</font> the discharge of <font color="blue">materials into</font> the <font color="blue">environment</font>, or     otherwise relating to the protection of the <font color="blue">environment</font></td>
    </tr>
    <tr>
      <td><font color="blue">Foreign Sales</font></td>
    </tr>
    <tr>
      <td>During 2005, 2004 and 2003, approximately dlra3cmam666cmam000,     dlra5cmam435cmam000 and dlra3cmam151cmam000, <font color="blue">respectively</font>, of our revenues were <font color="blue">from external</font>     <font color="blue">customers located</font> in <font color="blue">foreign countries</font></td>
    </tr>
    <tr>
      <td>Item 1A <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>We have experienced recent operating losses, working <font color="blue">capital <font color="blue">deficiencies</font></font>     and negative cash flows from <font color="blue">operations</font>, and these losses and <font color="blue">deficiencies</font>     <font color="blue">may continue</font> in the future</td>
    </tr>
    <tr>
      <td>Our recent operating losses, working <font color="blue">capital <font color="blue">deficiencies</font></font> and negative     cash flows from <font color="blue">operations</font> <font color="blue">may continue</font> in the future and there can be no     assurance that our <font color="blue">financial outlook will improve</font></td>
    </tr>
    <tr>
      <td>For the years ended     <font color="blue">December </font>31,  2005  and 2004, our operating losses were dlra7cmam479cmam000 and     dlra368cmam000, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>We experienced negative cash flows from <font color="blue">operations</font>     for the years ended <font color="blue">December </font>31, 2005 and 2004 of dlra148cmam000 and dlra3cmam461cmam000,     <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that our results of <font color="blue">operations</font> will     improve in the future</td>
    </tr>
    <tr>
      <td>If our results of <font color="blue">operations</font> do not improve in the     future, an <font color="blue">investment</font> in our <font color="blue">common stock could</font> be <font color="blue">negatively affected</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">invested significant resources</font> in the <font color="blue">development</font> of <font color="blue">lyophilization</font>     <font color="blue">manufacturing</font>  <font color="blue">capability</font>, and we may not realize the benefit of these     efforts and <font color="blue">expenditures</font></td>
    </tr>
    <tr>
      <td>8       _________________________________________________________________    [58]Table of <font color="blue">Contents       </font>     We  are in the process of completing an expansion of our Decatur,     Illinois <font color="blue">manufacturing</font> <font color="blue">facility</font> to <font color="blue">add capacity</font> to provide <font color="blue">lyophilization</font>     <font color="blue">manufacturing</font> services, a <font color="blue">manufacturing</font> <font color="blue">capability</font> we currently do not have</td>
    </tr>
    <tr>
      <td><font color="blue">Validation  </font>and  approval of the <font color="blue">lyophilization</font> <font color="blue">facility</font> by the FDA is     anticipated in the <font color="blue">second quarter</font> of 2006</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had spent approximately dlra19cmam691cmam000 on the     <font color="blue">lyophilization</font> expansion and anticipate the need to <font color="blue">spend approximately</font>     dlra1cmam000cmam000 of <font color="blue">additional</font> funds (excluding capitalized interest) which will     primarily be used for testing and <font color="blue">validation as</font> the <font color="blue">major capital equipment</font>     items  are  currently in place</td>
    </tr>
    <tr>
      <td>In addition, we are working toward the     <font color="blue">development</font> of an internal ANDA <font color="blue">lyophilized product pipeline</font></td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturing     </font><font color="blue">capabilities</font>  for <font color="blue">lyophilized products</font> are projected to be in place by     mid-2006</td>
    </tr>
    <tr>
      <td>However, there is no guarantee that we will be successful in     completing  <font color="blue">development</font>  of  <font color="blue">lyophilization</font>  <font color="blue">capability</font>, or that other     <font color="blue">intervening events will</font> not occur that reduce or eliminate the anticipated     <font color="blue">benefits from</font> such <font color="blue">capability</font></td>
    </tr>
    <tr>
      <td>For instance, the market for lyophilized     <font color="blue">products could significantly diminish</font> or be eliminated, or <font color="blue">new technological</font>     <font color="blue">advances could</font> render the <font color="blue">lyophilization</font> process obsolete, prior to our     <font color="blue">entry into</font> the market</td>
    </tr>
    <tr>
      <td>There can be no assurance that we will realize the     anticipated <font color="blue">benefits from</font> our significant <font color="blue">investment</font> into <font color="blue">lyophilization</font>     <font color="blue">capability</font> at our Decatur <font color="blue">manufacturing</font> <font color="blue">facility</font>, and our failure to do so     <font color="blue">could significantly limit</font> our ability to grow our business in the future</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> a small number of <font color="blue"><font color="blue">distributor</font>s</font>, the loss of any of <font color="blue">which could</font>     have a material adverse effect</td>
    </tr>
    <tr>
      <td>A small number of large <font color="blue">wholesale drug <font color="blue"><font color="blue">distributor</font>s</font> account</font> for a large     portion of our gross sales, revenues and <font color="blue">accounts receivable</font></td>
    </tr>
    <tr>
      <td>The following     three <font color="blue"><font color="blue">distributor</font>s</font>, AmerisourceBergen, <font color="blue">Cardinal </font>and McKesson, accounted for     approximately 69prca of total gross sales and 46prca of <font color="blue">total revenues</font> in 2005,     and 76prca of gross <font color="blue">trade receivables as</font> of <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>In addition to     acting  as  <font color="blue"><font color="blue">distributor</font>s</font>  of  our products, these <font color="blue">three companies also</font>     distribute a <font color="blue">broad range</font> of <font color="blue">health care products</font> for many other companies</td>
    </tr>
    <tr>
      <td>The loss of one or more of these <font color="blue"><font color="blue">distributor</font>s</font>, together with a delay or     <font color="blue">inability</font> to secure an <font color="blue">alternative</font> <font color="blue">distribution</font> source for end users, could     have a material <font color="blue">negative impact on</font> our revenue and results of <font color="blue">operations</font> and     lead to a violation of <font color="blue">debt covenants</font></td>
    </tr>
    <tr>
      <td>A change in purchasing patterns,     inventory levels, increases in returns of our products, delays in purchasing     products and delays in payment for <font color="blue">products by one</font> or more <font color="blue"><font color="blue">distributor</font>s</font> also     could  have  a  material <font color="blue">negative impact on</font> our revenue and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Certain of our <font color="blue">directors</font> are subject to conflicts of interest</td>
    </tr>
    <tr>
      <td>John N Kapoor, Ph</td>
    </tr>
    <tr>
      <td>D, our chairman of our board of <font color="blue">directors</font>, our     <font color="blue">chief executive officer from</font> March 2001 to <font color="blue">December </font>2002, and a principal     <font color="blue">shareholder</font>,  is  <font color="blue">affiliated</font>  with EJ Financial Enterprises, Inc</td>
    </tr>
    <tr>
      <td>(“EJ     Financial”), a health care consulting <font color="blue">investment</font> company</td>
    </tr>
    <tr>
      <td>EJ Financial is     involved in the <font color="blue">management</font> of <font color="blue">health care companies</font> in <font color="blue">various fields</font>, and     Dr</td>
    </tr>
    <tr>
      <td>Kapoor  is  involved in <font color="blue">various capacities with</font> the <font color="blue">management</font> and     operation of these companies</td>
    </tr>
    <tr>
      <td><font color="blue">The John N <font color="blue">Kapoor Trust </font></font>dated 9/20/89 (the     “Kapoor Trust”), the <font color="blue">beneficiary</font> and sole trustee of which is Dr</td>
    </tr>
    <tr>
      <td>Kapoor, is     a principal <font color="blue">shareholder</font> of each of these companies</td>
    </tr>
    <tr>
      <td><font color="blue">Kapoor     </font>does not devote his full time to our business</td>
    </tr>
    <tr>
      <td>Although <font color="blue">such companies</font> do     not currently compete directly with us, certain companies with which EJ     Financial is involved are in the <font color="blue">pharmaceutical</font> business</td>
    </tr>
    <tr>
      <td><font color="blue">Discoveries </font>made     by one or more of these <font color="blue">companies could</font> render our products less <font color="blue">competitive</font>     or obsolete</td>
    </tr>
    <tr>
      <td>The <font color="blue">Kapoor Trust </font>has also loaned us dlra5cmam000cmam000 resulting in     Dr</td>
    </tr>
    <tr>
      <td>Kapoor <font color="blue">effectively becoming</font> a major creditor of <font color="blue">ours as well as</font> a major     <font color="blue">shareholder</font></td>
    </tr>
    <tr>
      <td><font color="blue">Potential </font>conflicts of <font color="blue">interest could</font> have a material adverse     effect on our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may require <font color="blue">additional</font> capital to grow our business and <font color="blue">such funds may</font>     not be available to us</td>
    </tr>
    <tr>
      <td>We may require <font color="blue">additional</font> funds to grow our business</td>
    </tr>
    <tr>
      <td>However, adequate     funds  through  the <font color="blue">financial markets</font> or from other <font color="blue">sources may</font> not be     available  when  needed  or on terms favorable to us due to our recent     <font color="blue">financial history</font></td>
    </tr>
    <tr>
      <td>Further, the terms of such <font color="blue">additional</font> financing, if     obtained,  likely  will require the granting of rights, <font color="blue">preferences</font> or     privileges senior to those of our common stock and result in substantial     dilution of the <font color="blue">existing ownership interests</font> of our <font color="blue">common stockholders</font> and     could include covenants and <font color="blue">restrictions</font> that limit our ability to operate     or expand our business in a manner that we deem to be in our <font color="blue">best interest</font></td>
    </tr>
    <tr>
      <td>Our  growth  depends  on  our  ability  to  timely  develop <font color="blue">additional</font>     <font color="blue"><font color="blue">pharmaceutical</font> products</font> and <font color="blue"><font color="blue">manufacturing</font> <font color="blue">capabilities</font></font></td>
    </tr>
    <tr>
      <td>Our  strategy for growth is <font color="blue">dependent upon</font> our ability to develop     products that can be <font color="blue">promoted through current marketing</font> and <font color="blue">distribution</font>s     channels  and, when <font color="blue">appropriate</font>, the <font color="blue">enhancement</font> of <font color="blue">such marketing</font> and     <font color="blue">distribution</font> channels</td>
    </tr>
    <tr>
      <td>We may not meet our anticipated time schedule for the     filing of <font color="blue">ANDAs and NDAs </font>or may decide not to pursue <font color="blue">ANDAs or NDAs </font>that we     have submitted or anticipate submitting</td>
    </tr>
    <tr>
      <td>Our internal <font color="blue">development</font> of new     <font color="blue"><font color="blue">pharmaceutical</font> products</font> is <font color="blue">dependent upon</font> the research and <font color="blue">development</font>     <font color="blue">capabilities</font>  of  our  personnel  and  our strategic business alliance     <font color="blue">infrastructure</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that we or our strategic business     <font color="blue">alliances will successfully</font> develop new <font color="blue"><font color="blue">pharmaceutical</font> products</font> or, if     developed, <font color="blue">successfully integrate <font color="blue">new products</font> into</font>                                         9       _________________________________________________________________    [59]Table of <font color="blue">Contents       </font>our <font color="blue">existing product lines</font></td>
    </tr>
    <tr>
      <td>In addition, there can be no assurance that we     will receive all <font color="blue">necessary</font> FDA approvals or that <font color="blue">such approvals will</font> not     involve  delays,  <font color="blue">which adversely affect</font> the marketing and sale of our     products</td>
    </tr>
    <tr>
      <td>Our failure to develop <font color="blue">new products</font>, to maintain substantial     <font color="blue">compliance with</font> FDA <font color="blue">compliance guidelines</font> or to receive FDA approval of     ANDAs  or  NDAs, could have a material adverse effect on our business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">entered into</font> several strategic business <font color="blue">alliances which may</font> not     result in <font color="blue">marketable products</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">entered several strategic</font> business alliances that have been     formed to <font color="blue">supply us with low cost</font> finished dosage form products</td>
    </tr>
    <tr>
      <td>Since 2004,     we  have  <font color="blue">entered into</font> various purchase and supply <font color="blue">agreements</font>, license     <font color="blue">agreements</font>, and a <font color="blue">joint venture</font> that are all designed to provide finished     dosage form products that can be <font color="blue">marketed through</font> our <font color="blue">distribution</font> pipeline</td>
    </tr>
    <tr>
      <td>However, there can be no assurance that any of these <font color="blue">agreements</font> will result     in FDA-approved ANDAs or NDAs, or that we will be able to market any such     finished dosage form products at a profit</td>
    </tr>
    <tr>
      <td>In addition, any <font color="blue">clinical trial</font>     expenses that we incur may result in <font color="blue">adverse financial consequences</font> to our     business</td>
    </tr>
    <tr>
      <td>Our  success  depends  on  the  <font color="blue">development</font>  of generic and off-patent     <font color="blue"><font color="blue">pharmaceutical</font> products</font> which are <font color="blue">particularly susceptible</font> to <font color="blue">competition</font>,     <font color="blue"><font color="blue">substitution</font> policies</font> and <font color="blue"><font color="blue">reimbursement</font> policies</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">success depends</font>, in part, on our ability to anticipate which     branded <font color="blue">pharmaceutical</font>s are about to <font color="blue">come off patent</font> and <font color="blue">thus permit us</font> to     develop, <font color="blue">manufacture</font> and market equivalent generic <font color="blue"><font color="blue">pharmaceutical</font> products</font></td>
    </tr>
    <tr>
      <td>Generic <font color="blue">pharmaceutical</font>s must meet the <font color="blue">same quality standards as branded</font>     <font color="blue">pharmaceutical</font>s, even though these equivalent <font color="blue">pharmaceutical</font>s are sold at     prices that are <font color="blue">significantly lower than</font> that of branded <font color="blue">pharmaceutical</font>s</td>
    </tr>
    <tr>
      <td>Generic <font color="blue">substitution</font> is <font color="blue">regulated by</font> the federal and state <font color="blue">government</font>s, as     is <font color="blue">reimbursement</font> for <font color="blue">generic drug dispensing</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that     <font color="blue">substitution</font> will be permitted for <font color="blue">newly approved generic drugs</font> or that such     <font color="blue">products will</font> be subject to <font color="blue">government</font> <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>In addition, generic     products  that  third  parties develop may render our <font color="blue">generic products</font>     non<font color="blue">competitive</font> or obsolete</td>
    </tr>
    <tr>
      <td>There can be no assurance that we will be able     to consistently bring generic <font color="blue"><font color="blue">pharmaceutical</font> products</font> to <font color="blue">market quickly</font> and     <font color="blue">efficiently</font> in the future</td>
    </tr>
    <tr>
      <td>An increase in <font color="blue">competition</font> in the sale of generic     <font color="blue"><font color="blue">pharmaceutical</font> products</font> or our failure to <font color="blue">bring such products</font> to market     before our <font color="blue">competitors</font> could have a material adverse effect on our business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Further, there is <font color="blue">no proprietary protection</font> for most of the branded     <font color="blue"><font color="blue">pharmaceutical</font> products</font> that either we or other <font color="blue">pharmaceutical</font> companies     sell</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">government</font>al and cost-containment pressures regarding the     dispensing of generic <font color="blue">equivalents</font> will likely result in generic <font color="blue">substitution</font>     and  <font color="blue">competition</font> generally for our branded <font color="blue"><font color="blue">pharmaceutical</font> products</font></td>
    </tr>
    <tr>
      <td>We     attempt to mitigate the effect of this <font color="blue">substitution</font> through, among other     things,  creation  of  strong  brand-name recognition and product-line     <font color="blue">extensions</font> for our branded <font color="blue"><font color="blue">pharmaceutical</font> products</font>, but there can be no     assurance that we will be successful in these efforts</td>
    </tr>
    <tr>
      <td>10       _________________________________________________________________    [60]Table of <font color="blue">Contents       </font>We can be subject to <font color="blue">legal proceedings</font> against us, which may prove costly     and time-consuming even if meritless</td>
    </tr>
    <tr>
      <td>In the ordinary course of our business, we can be involved in legal     actions with both private parties and certain <font color="blue">government</font> agencies</td>
    </tr>
    <tr>
      <td>To the     extent that our personnel may have to spend time and resources to pursue or     contest any matters that may be asserted from time to time in the future,     this <font color="blue">represents</font> time and money that is not available for other actions that     we  might otherwise pursue <font color="blue">which could</font> be <font color="blue">beneficial</font> to our future</td>
    </tr>
    <tr>
      <td>In     addition, to the extent that we are <font color="blue">unsuccessful</font> in any <font color="blue">legal proceedings</font>,     the <font color="blue">consequences could</font> have a <font color="blue">negative impact on</font> our business, financial</td>
    </tr>
  </tbody>
</table>